Prolonged paradoxical response to anti-tuberculous treatment after infliximab

被引：15

作者：

Melboucy-Belkhir, Sara ^{[1
]}

Flexor, Gabriella ^{[1
]}

Stirnemann, Jerome ^{[1
]}

Morin, Anne-Sophie ^{[1
]}

Boukari, Latifatou ^{[1
]}

Polliand, Claude ^{[2
]}

Cruaud, Philippe ^{[3
]}

Fain, Olivier ^{[1
]}

机构：

[1] Univ Paris 13, Hop Jean Verdier, AP HP, Serv Med Interne, F-93140 Bondy, France

[2] Univ Paris 13, Hop Jean Verdier, AP HP, Serv Chirurg, F-93140 Bondy, France

[3] Univ Paris 13, Hop Jean Verdier, AP HP, Microbiol Lab, F-93140 Bondy, France

来源：

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2010年 / 14卷

关键词：

Tuberculosis; Anti-TNF; Cytokine; Spondylarthritis; Immunology; IMMUNE RECONSTITUTION; HIV; THERAPY;

D O I：

10.1016/j.ijid.2010.03.002

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

A 56-year-old woman with ankylosing spondylitis, treated for 3 months with infliximab, developed miliary tuberculosis with mediastinal lymphadenopathies and brain and splenic lesions. After initial improvement under anti-tuberculous therapy, she suffered an unexpectedly prolonged paradoxical worsening with several episodes of lymphadenopathy, including life-threatening ones, over a period of more than 14 months of follow-up. The outcome was favorable as a result of corticosteroid and surgical treatments. This phenomenon reflects a paradoxical reaction precipitated by infliximab withdrawal. (C) 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

引用

页码：E333 / E334

页数：2

共 10 条

[1]

Belknap R, 2005, INT J TUBERC LUNG D, V9, P1057

[2] Therapeutic Use of Infliximab in Tuberculosis to Control Severe Paradoxical Reaction of the Brain and Lymph Nodes [J].

Blackmore, Timothy K. ;

Manning, Laurens ;

Taylor, William J. ;

Wallis, Robert S. .

CLINICAL INFECTIOUS DISEASES, 2008, 47 (10) :E83-E85

[3] Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients [J].

Cheng, VCC ;

Ho, PL ;

Lee, RA ;

Chan, KS ;

Chan, KK ;

Woo, PCY ;

Lau, SKP ;

Yuen, KY .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (11) :803-809

[4] Paradoxical reactions in HIV and pulmonary TB [J].

Chien, JW ;

Johnson, JL .

CHEST, 1998, 114 (03) :933-936

[5] National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents [J].

Doherty, Sean D. ;

Van Voorhees, Abby ;

Lebwohl, Mark G. ;

Korman, Neil J. ;

Young, Melodie S. ;

Hsu, Sylvia .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 59 (02) :209-217

[6] Immune reconstitution in HIV-infected patients [J].

Hirsch, HH ;

Kaufmann, G ;

Sendi, P ;

Battegay, M .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (08) :1159-1166

[7] BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment [J].

Ormerod, LP ;

Milburn, HJ ;

Gillespie, S ;

Ledingham, J ;

Rampton, D .

THORAX, 2005, 60 (10) :800-805

[8]

Vidal CG, 2005, CLIN INFECT DIS, V40, P756, DOI 10.1086/427941

[9] Adalimumab Treatment of Life-Threatening Tuberculosis [J].

Wallis, Robert S. ;

van Vuuren, Cloete ;

Potgieter, Samantha .

CLINICAL INFECTIOUS DISEASES, 2009, 48 (10) :1429-1432

[10]

2003, REV MAL RESP, V20, pS41

← 1 →